Navigation Links
Study shows how retinoic acid enters a cell's nucleus

Cornell University researchers have revealed a process that has stumped scientists for many years: exactly how an acid derived from vitamin A enters a cell's nucleus, where it has strong anti-carcinogenic effects.

Discovery of this basic transport mechanism opens a new door for future research on related compounds. The finding has important implications for the fight against cancer and other diseases.

The research, which appears in a recent issue of the journal Molecular Cell (Vol. 18, No. 3), explains for the first time how the cancer-fighting vitamin A derivative retinoic acid (RA) gains entry into a cell's nucleus.

When vitamin A enters a cell's cytoplasm (the portion that lies between the outer membrane and the nucleus), it can be converted to RA, a member of a group of compounds that enter a cell's nucleus and play a role in triggering transcription. This is a basic process for relaying genetic information and switching genes on and off. In this role, RA can inhibit tumor growth. In fact, past clinical trials have shown that RA can help treat leukemia, head, neck and breast cancer. RA and its synthetic derivatives may also be useful in treatment of diabetes, arteriosclerosis and emphysema. Unfortunately, conventional treatments using RA require high, toxic doses, and tumors can develop resistance to the treatment.

Noa Noy, a professor of nutritional sciences at Cornell, and Richard Sessler, the paper's lead author and a graduate student in Noy's lab, wanted to learn how RA is transported into the cell's nucleus. The chemical structure of RA makes it hydrophobic, meaning it is barely soluble in water. But the path from the cell cytoplasm, where RA is made, to the nucleus requires passage through water, a difficult journey for a hydrophobic compound. For RA to rapidly enter a cell's nucleus, it must catch a ride on a water-soluble protein called cellular retinoic acid-binding protein type II (CRABP-II). This protein was discovered o ver two decades ago, but until recently scientists had no idea what it did.

Much like a doorway that requires a pass code to enter, CRABP-II can only move into a cell's nucleus if its amino acids are organized in a certain sequence, called a nuclear localization signal (NLS). However, CRABP-II does not have a recognizable NLS. Researchers have long wondered how proteins without an NLS enter a cell's nucleus.

By comparing the 3-D structures of the CRABP-II protein before and after it comes in contact with RA, Noy and Sessler made a startling discovery: When exposed to RA, three amino acids on the CRABP-II molecule flip their positions, exposing positive charges. Combined with the way the molecule is folded, this area suddenly looks like a classical NLS.

"This discovery creates a precedent for many other proteins that don't have an NLS, and it solves a mystery that has been in the literature for a long time," Noy says. "It explains a basic mechanism of how this protein, CRABP-II, gets into the nucleus, where it can act to suppress tumors."

CRABP-II is a member of a group of proteins called intracellular lipid binding proteins (ILBP), which don't have a recognizable NLS. But now researchers have something new to look for -- folds in a molecule's structure and amino acids that flip when exposed to a hormone or a drug. Noy currently is working with an ILBP that she has pinpointed as a pro-carcinogen -- it promotes cancer. Armed with new tools and knowledge, she hopes to figure out how to suppress the ability of this protein to move to the nucleus and promote cancer, perhaps by blocking the hormone that switches on its NLS.

In previous experiments with mice, Noy and her colleagues showed that by increasing CRABP-II levels within cells, tumor growth rates slow dramatically. The protein transfers RA rapidly and efficiently to the cell's nucleus. In this way, tumor growth may be inhibited using naturally occurring levels of RA, as oppo sed to the toxic doses currently administered.

"If you can provide a bus to get retinoic acid into the nucleus more efficiently, then you enhance its ability to act as an anti-carcinogen," says Noy. "It's a rapid transport advantage."

Her findings emphasize the importance of efforts in structural genomics, the study of the folding motifs in proteins, which allows researchers to compare 3-D structures of seemingly unrelated proteins. "Advances in structural genomics will allow you to predict what the protein does," Noy says.


Source:Cornell University News Service

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:

(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology: